JP3779798B2 - Ｃａ１２５の測定方法 - Google Patents
Ｃａ１２５の測定方法 Download PDFInfo
- Publication number
- JP3779798B2 JP3779798B2 JP17053497A JP17053497A JP3779798B2 JP 3779798 B2 JP3779798 B2 JP 3779798B2 JP 17053497 A JP17053497 A JP 17053497A JP 17053497 A JP17053497 A JP 17053497A JP 3779798 B2 JP3779798 B2 JP 3779798B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- measuring
- monovalent
- solid phase
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 31
- 239000002245 particle Substances 0.000 claims description 33
- 239000007790 solid phase Substances 0.000 claims description 19
- 239000003153 chemical reaction reagent Substances 0.000 claims description 17
- 238000005259 measurement Methods 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 230000004520 agglutination Effects 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 238000000691 measurement method Methods 0.000 claims description 2
- 239000004816 latex Substances 0.000 description 23
- 229920000126 latex Polymers 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- 230000002776 aggregation Effects 0.000 description 8
- 239000008055 phosphate buffer solution Substances 0.000 description 8
- 206010029719 Nonspecific reaction Diseases 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001235 sensitizing effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108010074605 gamma-Globulins Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012733 comparative method Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17053497A JP3779798B2 (ja) | 1997-06-26 | 1997-06-26 | Ｃａ１２５の測定方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17053497A JP3779798B2 (ja) | 1997-06-26 | 1997-06-26 | Ｃａ１２５の測定方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPH1114626A JPH1114626A (ja) | 1999-01-22 |
| JPH1114626A5 JPH1114626A5 (enExample) | 2005-04-14 |
| JP3779798B2 true JP3779798B2 (ja) | 2006-05-31 |
Family
ID=15906708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17053497A Expired - Fee Related JP3779798B2 (ja) | 1997-06-26 | 1997-06-26 | Ｃａ１２５の測定方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3779798B2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050083774A (ko) | 2002-10-16 | 2005-08-26 | 유로-셀티크 소시에떼 아노뉨 | 세포-연관된 ｃａ 125/ｏ772ｐ에 결합하는 항체들 및그것의 용도의 방법들 |
| CN111721938B (zh) * | 2019-03-29 | 2022-11-25 | 北京九强生物技术股份有限公司 | 糖链抗原125胶乳免疫比浊试剂盒 |
-
1997
- 1997-06-26 JP JP17053497A patent/JP3779798B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH1114626A (ja) | 1999-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3197277B2 (ja) | 一種類以上の免疫学的配位子の分析方法，その分析試薬およびそのキット | |
| JP3364537B2 (ja) | 非競合結合検定方法 | |
| US20070166776A1 (en) | Immunoassay and kit for an early and simultaneous detection of biochemical markers in a patient's sample | |
| KR920000056B1 (ko) | 특이적으로 결합가능한 물질의 측정방법 | |
| EP0185722A1 (en) | Polyclonal antibodies, preparation and use | |
| US6764825B1 (en) | Methods and device for detecting prostate specific antigen (PSA) | |
| WO2010114514A1 (en) | Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer | |
| KR920000057B1 (ko) | 특이적으로 결합가능한 물질의 측정 방법 및 시약 | |
| US4968604A (en) | Method and test kit for detection of antibodies | |
| JP3833358B2 (ja) | 被検体の亜集団の測定のための均一検出方法 | |
| JPH03229153A (ja) | リュウマチ病の診断に有用な特異的抗体または抗原の存在を検出する方法およびそれに用いられるテストキット | |
| KR20130090892A (ko) | 면역분석에서 시약의 반응성을 조절하기 위한 공동 결합 | |
| JP3779798B2 (ja) | Ｃａ１２５の測定方法 | |
| US20100248269A1 (en) | Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer | |
| EP0106615A2 (en) | Assay for the free portion of substances in biological fluids | |
| JPS6223823B2 (enExample) | ||
| US6927071B2 (en) | Method for reducing non-specific aggregation of latex microparticles in the presence of serum or plasma | |
| US5436132A (en) | Quantitative determination of tenascin as glioma marker | |
| JPH0727763A (ja) | １α，２５（ＯＨ）２ビタミンＤ３に対する抗体及びその用途 | |
| JP2931111B2 (ja) | 癌診断剤 | |
| JP2651438B2 (ja) | 酵素標識抗体感作ラテックス及びそれを用いた酵素免疫測定法 | |
| JP3102827B2 (ja) | 特異的結合アッセイ試薬及びそれを使用した測定方法 | |
| EP0131096A2 (en) | Homogeneous immunoassay method for determining binding substances and reagent system therefor | |
| AU2002346529B2 (en) | Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample | |
| JP3269401B2 (ja) | 免疫測定方法及びその測定試薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040609 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040609 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050817 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050823 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050915 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060202 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060303 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090310 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120310 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120310 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150310 Year of fee payment: 9 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |